G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? But no need to fret. We have assembled a menu of tidbits to help you along and invite you to join us for a cup of stimulation — vanilla macadamia nut, in our case — to cope. So dig in and have a great day. …

Teva Pharmaceuticals (TEVA) hired Lundbeck’s (LUN) Kare Schultz as its new chief executive, ending a seven-month search for a new leader to jumpstart sales, lower debt, and restore investor confidence after a controversial acquisition spree. Schultz, 56, who has been running Lundbeck and will move to Israel, faces pressure to either to maintain Teva as both a generics and specialty drug maker, split the company in two, or exit generics altogether.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.